Phase III randomised chemoprevention study of Selenium on the recurrence of non-invasive bladder cancer. The SELEnium and BLAdder cancer Trial (SELEBLAT)

被引：0
|
作者：
Goossens M. [1 ]
Zeegers M. [2 ]
Van Poppel H. [3 ,4 ]
Joniau S. [3 ,4 ]
Ackaert K. [5 ]
Ameye F. [6 ]
Billiet I. [7 ]
Dillen K. [8 ]
Goeman L. [9 ]
Van Bruwaene S. [3 ,4 ]
Van der Aa F. [3 ,4 ]
Vekemans K. [8 ]
Buntinx F. [1 ]
机构：
[1] KU Leuven, Leuven
[2] University Maastricht, Maastricht
[3] UZ Leuven, Leuven
[4] UZ Leuven, Leuven
[5] Sint-Elisabethziekenhuis, Turnhout
[6] AZ Maria Middelares, Gent
[7] AZ Groeninge, Kortrijk
[8] Jessa ziekenhuis, Hasselt
[9] H. Hart ziekenhuis, Roeselaere
来源：
Archives of Public Health | / 73卷 / Suppl 1期
关键词：
Selenium; Bladder Cancer; Standard Care; Transitional Cell Carcinoma; Selenium Concentration;
D O I：
10.1186/2049-3258-73-S1-P5
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [31] A multiplex immunoassay for the non-invasive detection of bladder cancer
    Yoshiko Shimizu
    Hideki Furuya
    Peter Bryant Greenwood
    Owen Chan
    Yunfeng Dai
    Mark D. Thornquist
    Steve Goodison
    Charles J. Rosser
    Journal of Translational Medicine, 14
  • [32] Non-invasive bladder cancer presenting with renal failure
    Dogra, PN
    Kumar, R
    Goel, A
    UROLOGIC ONCOLOGY, 2001, 6 (03): : 95 - 96
  • [33] Non-invasive detection of bladder cancer by electromagnetic interaction
    Esperto, F.
    Kastner, C.
    Patel, K.
    De Nunzio, C.
    Tubaro, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E439 - U960
  • [34] Phase III prevention trial of Fenretinide in patients with resected non-muscle-invasive bladder cancer
    Sabichi, Anita L.
    Lerner, Seth P.
    Atkinson, E. Neely
    Grossman, H. Barton
    Caraway, Nancy P.
    Dinney, Colin P.
    Penson, David F.
    Matin, Surena
    Kamat, Ashish
    Pisters, Louis L.
    Lin, Daniel W.
    Katz, Ruth L.
    Brenner, Dean E.
    Hemstreet, George P., III
    Wargo, Mary
    Bleyer, Archie
    Sanders, William H.
    Clifford, John L.
    Parnes, Howard L.
    Lippman, Scott M.
    CLINICAL CANCER RESEARCH, 2008, 14 (01) : 224 - 229
  • [35] Organ preservation strategies in bladder cancer and the results of BC2001 trial, a Phase III trial of chemoradiotherapy in muscle invasive bladder cancer
    Hussain, Syed A.
    James, Nicholas D.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 24 : S82 - S82
  • [36] Celecoxib for the treatment of non muscle invasive bladder cancer. Results from the first phase II clinical trial
    Pagliarulo, V.
    Martines, I.
    Telari, S.
    Ancona, P.
    Trerotoli, P.
    Albo, G.
    Pagliarulo, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 299 - 299
  • [37] A Randomized Pilot Trial of Dietary Modification for the Chemoprevention of Noninvasive Bladder Cancer: The Dietary Intervention in Bladder Cancer Study
    Parsons, J. Kellogg
    Pierce, John P.
    Natarajan, Loki
    Newman, Vicky A.
    Barbier, Leslie
    Mohler, James
    Rock, Cheryl L.
    Heath, Dennis D.
    Guru, Khurshid
    Jameson, Michael B.
    Li, Hongying
    Mirheydar, Hossein
    Holmes, Michael A.
    Marshall, James
    CANCER PREVENTION RESEARCH, 2013, 6 (09) : 971 - 978
  • [38] Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer
    A. Brunner
    C. Ensinger
    M. Christiansen
    S. Heiss
    I. Verdorfer
    G. Mikuz
    A. Tzankov
    Virchows Archiv, 2007, 450 : 659 - 664
  • [39] Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer
    Brunner, A.
    Ensinger, C.
    Christiansen, M.
    Heiss, S.
    Verdorfer, I.
    Mikuz, G.
    Tzankov, A.
    VIRCHOWS ARCHIV, 2007, 450 (06) : 659 - 664
  • [40] Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
    Descotes, Francoise
    Kara, Norelyakin
    Decaussin-Petrucci, Myriam
    Piaton, Eric
    Geiguer, Florence
    Rodriguez-Lafrasse, Claire
    Terrier, Jean E.
    Lopez, Jonathan
    Ruffion, Alain
    BRITISH JOURNAL OF CANCER, 2017, 117 (04) : 583 - 587
12345